RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

Study Overview
=================
Brief Summary
-----------------
Primary objective: To check if RotaTeq® can be administered concomitantly with meningococcal Group C vaccine without impairing the efficacy of MCC vaccine. The hypothesis tested is that the seroprotection rate for MMC at 28 days after the second MCC vaccination with concomitant administration of RotaTeq® is non-inferior to that without non-concomitant (sequential) administration of RotaTeq®.

Official Title
-----------------
An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of the Concomitant Use of a Live Pentavalent Rotavirus Vaccine (RotaTeq®) and a Meningococcal Group C Conjugate (MCC) Vaccine in Healthy Infants

Conditions
-----------------
Meningitis, Meningococcal, Rotavirus Infections

Intervention / Treatment
-----------------
* Biological: RotaTeq®
* Biological: NeisVac-C®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy infants, aged from 6 weeks through full 7 weeks, Consent form signed by at least one parent or by the legal representative properly informed about the study, Parent(s) / legal representative able to understand the protocol requirements and to fill in the Diary Card. Exclusion Criteria: History of congenital abdominal disorders, congenital malformation of the gastrointestinal tract that could predispose to intussusception, or abdominal surgery, Congenital fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency, Known or suspected impairment of immunological function, Known hypersensitivity to any component of RotaTeq® (e.g. sucrose) or of NeisVac-C® (including tetanus toxoid), Prior administration of any rotavirus vaccine, Prior administration of any vaccine within the 28 days prior to randomisation, Fever (rectal temperature ≥38.1°C) and/or acute diarrhoea and/or vomiting at randomisation, History of known prior rotavirus gastroenteritis, chronic diarrhoea, or failure to thrive, Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection, Clinical evidence of active gastrointestinal illness, Receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 14 days prior to randomisation. Note: Infants on inhaled and/or topical steroids may participate in the study, Infants residing in a household with an immunocompromised person, Prior receipt of a blood transfusion or blood products, including immunoglobulins.

Ages Eligible for Study
-----------------
Minimum Age: 42 Days
Maximum Age: 55 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group 1: Concomitant Administration<br>Participants received 2 concomitant doses of RotaTeq® and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age and a third dose of RotaTeq® at 24-25 weeks of age (and 28 to 42 days after the vaccine administration at 20-21 weeks of age). | Biological: RotaTeq®<br>* Rotavirus vaccine, live, oral, pentavalent, 2 mL solution for oral administration.<br>* Other names: V260;Biological: NeisVac-C®<br>* Meningiococcal Group C Polysaccharide Conjugate Vaccine Absorbed, 0.5 mL suspension for intramuscular injection.<br>|
| Active Comparator: Group 2: Sequential Administration<br>Participants received 3 doses of RotaTeq® at 6-7 weeks of age, 15-16 weeks of age, and 24-25 weeks of age (and 28 to 42 days after the MMC vaccine administered at 20-21 weeks of age), and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age. | Biological: RotaTeq®<br>* Rotavirus vaccine, live, oral, pentavalent, 2 mL solution for oral administration.<br>* Other names: V260;Biological: NeisVac-C®<br>* Meningiococcal Group C Polysaccharide Conjugate Vaccine Absorbed, 0.5 mL suspension for intramuscular injection.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants Achieving Seroresponse for Meningiococcal Group C Serotype | Antibody seroprotection to meningiococcal Group C serotype was measured by serum bactericidal antibody with rabbit complement (sRBA). The criterion for seroresponse was an sRBA titer >=1:8. | 28 days after the second dose of MCC vaccine (approximately 20 weeks) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prevention of Gastroenteritis due to rotavirus infection. And prevention of Invasive disease caused by Neisseria meningitidis serogroup C.